Comparative Pharmacology
Head-to-head clinical analysis: VOYXACT versus XPOVIO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: VOYXACT versus XPOVIO.
VOYXACT vs XPOVIO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
GABAA receptor positive allosteric modulator; a neuroactive steroid that potentiates GABAergic inhibition.
Selective inhibitor of nuclear export (SINE) that binds to and inhibits exportin 1 (XPO1), blocking the nuclear export of tumor suppressor proteins (e.g., p53, IκB) and growth regulators, leading to their nuclear accumulation and reactivation, thereby inducing apoptosis in cancer cells.
Adults: 200 mg orally once daily with food.
XPOVIO (selinexor) is administered orally at a dose of 80 mg (four 20 mg tablets) on days 1 and 3 of each week for multiple myeloma. For diffuse large B-cell lymphoma, the recommended dose is 60 mg (three 20 mg tablets) on days 1 and 3 of each week.
None Documented
None Documented
Terminal elimination half-life approximately 37 hours (range 24-51 hours), supporting once-daily dosing with steady-state achieved in 5-8 days.
Terminal half-life ranges from 6 to 10 hours (mean ~7.5 h) in patients with relapsed/refractory multiple myeloma; supports twice-weekly dosing with food.
Primarily hepatic metabolism via CYP3A4, with 53% of the dose excreted in feces (mainly as metabolites) and 27% in urine (mostly as metabolites); less than 1% excreted unchanged in urine.
Primarily metabolized by CYP3A4 and other pathways; <1% excreted unchanged in urine; fecal excretion accounts for ~80% of total clearance, with renal elimination minimal (<2% of dose).
Category C
Category C
Antineoplastic
Antineoplastic